Genmab’s Petosemtamab Combination Cuts Death Risk 50% in Phase 3 Head and Neck Cancer Trial
Bitget2026/10/28 13:41- Genmab reported positive Phase 3 LiGeR-HN1 results for petosemtamab with pembrolizumab in first-line PD-L1-positive recurrent or metastatic head and neck cancer.
- The combination significantly improved overall survival and tumor response versus pembrolizumab alone at the first interim analysis, meeting both primary endpoints.
- Benefits were observed regardless of HPV status; no new safety signals emerged.
- Global regulatory discussions are planned, with full trial results to be submitted for presentation at a future medical meeting.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
